<DOC>
	<DOCNO>NCT00083538</DOCNO>
	<brief_summary>The purpose study determine vaccination autologous idiotype- tumor lysate-pulsed dendritic cell induces generation anti-idiotypic anti-tumor immunologic response .</brief_summary>
	<brief_title>Study Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously Intranodally</brief_title>
	<detailed_description>This experimental treatment consist receive special white blood cell administration either underneath skin lymph node . In protocol , treatment give accord `` risk group '' . If certain abnormality chromosome , disease consider high risk . High-risk patient first receive one cycle chemotherapy regimen call DT PACE , white blood cell collect . Leukapheresis procedure blood remove , white blood cell save , remain blood give back . These dendritic cell mixed individual myeloma protein and/or cell , keyhole limpet hemocyanin ( KLH ) necessary enhancement immune response myeloma antigens . It hop cause cell interact activate T cell , destroy myeloma cell body . Half white cell inject lymph node ( intranodally ) half give subcutaneously . High risk patient receive chemotherapy regimen call DT PACE .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients must confirm diagnosis one following : Smoldering indolent multiple myeloma , Multiple myeloma 1 year autologous transplant stable disease , Multiple myeloma cytogenetic abnormality Patients secretory IgA IgG must purify idiotype protein available and/or tumor cell available , patient light chain nonsecretory myeloma must tumor cell available Karnofsky performance score great equal 60 ANC great equal 1,000/microliters , platelet count great equal 60,000/microliters , CD4 count great equal 400/microliters . Expected survival 3 month 18 year age old Have give write consent inform investigational nature study . Negative serology HIV , Hepatitis C , negative hepatitis B surface antigen Patients CD4 count &lt; 400/microliters , and/or severely damage immune function Chemotherapy immunosuppressive treatment steroid , cytoxan , methotrexate within 8 week Fever active infection Liver function : total bilirubin great equal 2 x ULN AST/ALT great equal 3 x ULN Renal function : Patients dialysis Simultaneous treatment second investigational drug biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>DTPACE</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Dendritic Cell Vaccination</keyword>
	<keyword>Leukapheresis</keyword>
</DOC>